Loading...
Loading...
FENC| Name | Value |
|---|---|
| Revenues | 25.3M |
| Cost of Revenue | 0.5M |
| Gross Profit | 24.7M |
| Operating Expense | 11.0M |
| Operating I/L | 13.7M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.2M |
| Pretax | 12.8M |
| Income Tax Expense | -0.7M |
| Net Income/Loss | 12.8M |
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company's primary source of revenue is expected to come from the commercialization of PEDMARK, once it receives regulatory approval. As a clinical-stage company, Fennec Pharmaceuticals Inc. is dedicated to advancing its product candidate through the development process to bring a potentially life-changing treatment to market.
